Financial Performance - The company's operating revenue for 2024 reached ¥12,021,863,029.21, an increase of 4.77% compared to ¥11,474,162,365.59 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥1,031,121,698.55, a decrease of 2.29% from ¥1,055,340,740.79 in 2023[22]. - The net profit after deducting non-recurring gains and losses was ¥984,439,126.95, down 4.09% from ¥1,026,437,851.58 in 2023[22]. - The cash flow from operating activities increased by 17.20% to ¥1,208,753,683.01 from ¥1,031,363,074.08 in 2023[22]. - Basic earnings per share for 2024 were ¥0.8864, a decrease of 1.78% from ¥0.9025 in 2023[22]. - The total assets at the end of 2024 were ¥12,729,008,610.16, a slight decrease of 0.30% from ¥12,767,664,072.34 at the end of 2023[22]. - The net assets attributable to shareholders increased by 8.34% to ¥6,741,964,785.16 from ¥6,222,728,875.43 at the end of 2023[22]. - The company reported a quarterly revenue of ¥3,198,046,619.86 in Q1 2024, with a net profit of ¥243,716,289.99 attributable to shareholders[26]. - The weighted average return on equity for 2024 was 16.09%, down from 18.17% in 2023[22]. - The gross profit margin for the pharmaceutical main business was 23.84%, a decrease of 1.76% from the previous year[74]. Research and Development - Research and development expenses for the company reached ¥64,147.18 million in 2024, representing a year-on-year increase of 2.66% and accounting for 5.34% of total revenue[39]. - The company has a total of 1,156 R&D personnel, including 54 PhDs and 405 Master's degree holders[39]. - The company is focusing on innovation and has established multiple technology centers across its business segments to enhance R&D capabilities[39]. - The company has strengthened its project application and patent acquisition processes, although specific numbers were not disclosed in the report[40]. - The company has submitted 409 patent applications, with 145 valid patents, including 134 inventions and 11 utility models[41]. - The company has established eight major technology platforms to support its API and CDMO businesses, enhancing its competitive edge in the market[56]. Market and Industry Outlook - The global pharmaceutical market is projected to reach $2.5 trillion by 2030, driven by an aging population and increasing healthcare demands[33]. - The Chinese pharmaceutical market is expected to grow to ¥2.89 trillion by 2030, capturing approximately 1/6 of the global market share[34]. - The company is actively involved in the production and sales of various pharmaceutical products, including APIs and innovative drug development services[38]. - The company is advancing its "2030 development strategy," focusing on refining raw materials, strengthening CDMO, and expanding into medical aesthetics[66]. Environmental Compliance - The company has established a comprehensive EHS management system, with 11 wastewater treatment systems capable of processing 5.4 million tons of wastewater annually[48]. - The company has implemented a "three simultaneous" system for new projects, ensuring environmental impact assessments are conducted alongside construction[154]. - The company is committed to enhancing its environmental monitoring capabilities as per national guidelines[153]. - The company is focusing on compliance with the latest environmental regulations, including the 2024 version of the Industrial Structure Adjustment Guidance Catalog[152]. - The company has achieved a reduction in various pollutants, with emissions from waste gas treatment facilities consistently below national and local standards[169]. Corporate Governance - The company operates under a "business unit + functional" management structure, which includes four business units and various functional departments[111]. - The company emphasizes independence from its controlling shareholders in terms of assets, personnel, and financial operations[113]. - The company has implemented internal control measures in accordance with its internal control implementation guidelines[112]. - The company has established a performance-based salary system for senior management, linking remuneration to both company and individual performance[126]. - The company has not reported any significant discrepancies in its governance practices compared to regulatory requirements[112]. Shareholder Returns - The company plans to distribute a cash dividend of ¥3.56 per 10 shares, totaling approximately ¥413,000,000 based on the adjusted share capital[5]. - The company reported a cash dividend of 412,405,913.06 CNY, with a total cash dividend including other methods amounting to 612,608,349.59 CNY, representing 100% of the total profit distribution[140]. - The company has a profit distribution policy that mandates a minimum cash dividend ratio of 40% during profit distribution when in a mature development stage with significant capital expenditure plans[140]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[116]. - The company is currently in the process of submitting domestic and international application materials for several products, indicating ongoing expansion efforts[85]. - The company is committed to enhancing its production capabilities while managing associated uncertainties in the development process[83]. - The company is pursuing multiple avenues for product line expansion, with several projects currently under review for market approval[84]. Employee and Talent Management - The company has recruited 21 key talents, including 11 PhDs, and hired 568 recent graduates in relevant fields to support innovation and capacity expansion[49]. - The company conducted a training needs survey in October, with an annual training plan developed by December based on strategic development needs[138]. - The total number of employees at the end of the reporting period is 7,060, with 4,281 in production, 1,774 in technical roles, and 339 in sales[135][136].

普洛药业股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年2月19日召开第九届 董事会第十次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司股权激励和员工 持股计划。本次回购股份价格不超过人民币22元/股（含），回购资金总额不低 于人民币7,500万元（含）且不超过人民币15,000万元（含）。具体回购股份数 量以回购期限届满或回购股份实施完毕时实际回购股份数量为准。回购期限为自 公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司分别于 2025 年 2 月 20 日 、 2025 年 2 月 21 日 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《第九届董事会第十次会议决议公告》 （公告编号：2025-04）、《关于回购公司股份方案的公告》（公告编号：2025-05） 及《关于回购股份的报告书》（公告编号：2025-06 ...

普洛药业股份有限公司 关于回购股份的报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000739 证券简称：普洛药业 公告编号：2025-06 重要内容提示： 1.普洛药业股份有限公司（以下简称"公司"）于 2025 年 2 月 19 日召开第 九届董事会第十次会议，经全体董事审议，一致通过了《关于回购股份方案的议 案》。根据《公司章程》的相关规定，本次回购股份方案属于董事会审批权限范 围，无需提交股东大会审议。 2.公司拟使用自有资金以集中竞价交易方式回购公司股份，本次回购资金总 额为人民币 7,500 万元—15,000 万元，本次回购股份价格不超过人民币 22 元/ 股，未超过公司董事会通过回购股份决议前三十个交易日公司股票交易均价的 150%。具体回购数量以回购期限届满或者回购股份实施完毕时实际回购的股份数 量为准。回购期限为自董事会审议通过回购股份方案之日起 12 个月内。 3.公司已在中国证券登记结算公司深圳分公司开立了回购股份专用账户。 4.截止本公告披露日，公司持股 5%以上股东无减持计划。 5.相关风险提示 （1）本次回购存 ...

普洛药业股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东 持股情况的公告 证券代码：000739 证券简称：普洛药业 公告编号：2025-07 普洛药业股份有限公司（以下简称"公司"）于2025年2月19日召开了第九 届董事会第十次会议，审议通过了《关于回购公司股份方案的议案》，并于2025 年2月20日在《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）披露了 《关于公司回购股份方案的公告》（公告编号：2025-05）。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关规定，现将公司董事会公告回购股份决议的前一个 交易日（即2025年2月19日）登记在册的前十名股东和前十名无限售条件股东名 称、持股数量及占总股本比例情况公告如下： | 序号 | 持股人名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 横店集团控股有限公司 | 330,941,729 | 28.30 | | 2 | 浙江横店进出口有限公司 | 156,552,903 | 13.39 | | ...

第九届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司拟使用自有资金通过深圳证券交易所交易系统以集中竞价交易方式回 购公司股份，回购股份价格不超过人民币 22 元/股，回购资金总额：不低于人民 币 7,500 万元（含）且不超过人民币 15,000 万元（含）。在回购价格不超过人 民币 22 元/股的条件下，按回购金额上下限测算，预计可回购股份数量为 340 万股—682 万股，约占公司总股本的 0.29%—0.58%。具体回购股份的数量和金额 以回购期限届满或者回购股份实施完毕时实际回购的股份数量和金额为准。回购 期限为自董事会审议通过回购股份方案之日起 12 个月内。若公司在股份回购完 成后 36 个月内未能实施前述用途，未使用部分将依法履行相关程序后予以注销。 表决结果：7 票同意、0 票反对、0 票弃权 证券代码：000739 证券简称：普洛药业 公告编号：2025-04 普洛药业股份有限公司 普洛药业股份有限公司（以下简称"公司"）第九届董事会第五次会议通知 于2025年2月9日以短信及电子邮件等方式发出。会议于2025 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-05 普洛药业股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1. 普洛药业股份有限公司（以下简称"公司"）拟使用自有资金通过深圳 证券交易所交易系统以集中竞价交易方式回购公司股份，主要内容如下： （1）回购股份的用途：本次回购股份拟用于股权激励或员工持股计划。若 公司在股份回购完成后 36 个月内未能实施前述用途，未使用部分将依法履行相 关程序后予以注销。 （2）回购资金总额：本次回购资金总额不低于人民币 7,500 万元（含）且 不超过人民币 15,000 万元（含）。 （3）回购价格：本次回购股份价格不超过人民币 22 元/股（含），未超过 公司董事会通过回购股份决议前三十个交易日公司股票交易均价的 150%。若公 司在本次回购股份期限内发生派发红利、送红股、资本公积金转增股本等除权除 息事项，自股价除权除息之日起，按照中国证监会及深圳证券交易所的相关规定 相应调整回购价格上限。 （4）回购期限：自公司董事会审议通过本次回购股份方案之 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-03 普洛药业股份有限公司 3、2025 年 1 月 20 日，公司与农业银行签订《保证合同》（合同编号： 33100120250001245），同意为公司全资子公司家园药业与农业银行签署的《商 业汇票银行承兑合同》（合同编号：33180120250001884）中的 3,000 万元银行 承兑汇票提供连带责任保证，担保期限 6 个月。 4、2025 年 1 月 17 日，公司与中国银行签订《保证合同》（合同编号：横 店 2025 人保字 017 号），同意为公司全资子公司家园药业与中国银行签署的《商 业汇票承兑协议》（合同编号：横店 2025 人承字 017 号）中的 3,000 万元银行 承兑汇票提供连带责任保证，担保期限 6 个月。 5、2025 年 1 月 16 日，公司与中国银行签订《保证合同》（合同编号：横 店 2025 人保字 010 号），同意为公司全资子公司浙江普洛得邦制药有限公司（以 下简称"得邦制药"）与中国银行签署的《流动资金借款合同》（合同编号：横 店 2025 人借字 010 号）中的流动资金贷款 3,000 万元提供 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3]. Core Views - The core investment logic highlights the sustained high demand for antibiotic raw materials, with an anticipated turning point for florfenicol. The company's raw material business is expected to maintain stable growth. The entry into the CDMO market demonstrates resilience amid overall market pressures, supported by enhanced R&D capabilities, significant production advantages, and quality customer resources. The integration of raw materials and formulations provides a competitive edge, with new products expected to accelerate growth [1][2]. Summary by Sections Company Overview - The company has a comprehensive industry layout, having evolved from raw material intermediates to include formulations and CDMO services over its 30-year history. It operates seven raw material factories and two formulation factories, with R&D centers in multiple locations, establishing itself as a significant player in the domestic pharmaceutical industry [13][15]. Raw Material Business - The raw material segment, particularly antibiotics, remains a core pillar with a complete industrial chain from core intermediates to formulations. The company is the largest domestic supplier of cefixime raw materials and is positioned to benefit from the anticipated recovery in downstream demand [1][2][15]. CDMO Business - The CDMO segment has shown resilience, with a significant increase in project quotations and ongoing projects. The company has established solid partnerships with 414 global innovative drug companies, including major multinational corporations [2][15]. Formulation Business - The formulation segment is expanding with a diverse product portfolio, leveraging the integration of raw materials and formulations. The company actively participates in centralized procurement policies, with approximately 45% of its formulation business involved in such initiatives [2][15]. Financial Forecast and Valuation - The company is projected to achieve net profits of 1.109 billion, 1.282 billion, and 1.527 billion yuan for 2024, 2025, and 2026, respectively, with corresponding P/E ratios of 16X, 14X, and 12X. The report expresses optimism about the company's growth trajectory [3][4].

司 研 华福证券 普洛药业（000739.SZ） 原料药-CDMO-制剂三维共振，业绩有望提速 投资要点： 原料药行业周期底部向上，多重催化下长期成长空间有望开启 2023 年国内原料药产业受 22 年疫情相关订单导致的高基数以及 下游制剂厂商消化疫情期间的库存影响，包括公司在内的多家原料药 企业业绩出现短期波动。当前原料药产量单月同比增长明显，24H1 国 内原料药产量同比回正，出口量持续增长，或意味着原料药去库存已 接近尾声，需求端有望提振。同时考虑到海外专利悬崖下仿制药原料 药及制剂出海空间巨大，原料药-制剂一体化企业有望充分受益。 原料药业务为基石，人用及兽用药双轮驱动 公司深耕原料药领域 30 余载，原料药、中间体业务近年来产销率 水平高，表现出良好的经营韧性。2024H1 公司该业务营收入达 47.0 亿元，同比增长 11.9%。公司产品品类丰富，领域涵盖人用、兽用药 物原料药和中间体，并陆续推出原料药新品种，2024H1 有 2 个 API 品种注册获批，20 个原料药品种新递交国内外 DMF。公司原料药产 品目前获美国DMF认证的原料药25个品种，目前处于有效期内的 CEP 证书 10 个，有 ...

Investment Rating - The report gives a "Buy" rating for the company with a target price of 20.20 yuan [6] Core Views - The company is a comprehensive API leader transitioning to CDMO and formulation development, leveraging its API foundation to build a global CDMO service platform [1] - The company's CDMO business has formed a funnel-shaped structure, with rapid growth in project numbers and clients, indicating strong future performance potential [4] - The company's API business is stable, with new product layouts enhancing competitiveness, especially in the medical aesthetics and cosmetics sector [2] - The formulation business is optimizing, with a diversified product pipeline and stable sales growth [3] - The company is expected to achieve revenue of 12.403 billion yuan in 2024, with a year-on-year growth of 8.10%, and net profit of 1.111 billion yuan, with a year-on-year growth of 5.29% [5] Business Segments API Business - The company is a leading domestic API manufacturer with a strong market position in products like cefixime, bupropion hydrochloride, and amoxicillin side chain series [2] - The company has established a medical aesthetics and cosmetics API division, focusing on synthetic biology, chemical synthesis, and peptide technologies [2] - The API business is expected to maintain stable growth due to good international certifications and accelerated synthetic biology layout [5] Formulation Business - The company has over 120 formulation products, covering anti-infective, cardiovascular, central nervous system, and other therapeutic areas [3] - The formulation business is accelerating a "multi-product" strategy, with 25 new projects underway, focusing on anti-infective, cardiovascular, and central nervous system drugs [3] - The formulation business is expected to benefit from the company's API integration advantage and centralized procurement processes [5] CDMO Business - The CDMO business has seen double-digit growth in revenue and profit, with project structure optimization [4] - In H1 2024, the company had 731 quoted projects, a 51% year-on-year increase, and 876 ongoing projects, a 44% year-on-year increase, including 317 commercial-stage projects [4] - The CDMO business is expected to achieve rapid growth in the future, leveraging its global R&D centers and funnel-shaped project structure [5] Financial Projections - The company is expected to achieve revenue of 12.403 billion yuan in 2024, 13.739 billion yuan in 2025, and 15.194 billion yuan in 2026, with year-on-year growth rates of 8.10%, 10.77%, and 10.59% respectively [5] - Net profit is expected to be 1.111 billion yuan in 2024, 1.243 billion yuan in 2025, and 1.392 billion yuan in 2026, with year-on-year growth rates of 5.29%, 11.88%, and 11.99% respectively [5] - The company's P/E ratio is expected to be 16.77 in 2024, 14.99 in 2025, and 13.39 in 2026 [5] Strategic Developments - The company has established a medical aesthetics and cosmetics API division, focusing on synthetic biology, chemical synthesis, and peptide technologies [2] - The company has formed a strategic partnership with BaiKuiRui to advance synthetic biology applications in biopharmaceuticals, APIs, and intermediates [90] - The company is investing in new production lines and expanding its API and intermediate product portfolio to meet market demand [89]